CRISPR Therapeutics Management
Management criteria checks 3/4
CRISPR Therapeutics' CEO is Sam Kulkarni, appointed in Dec 2017, has a tenure of 7.17 years. total yearly compensation is $12.32M, comprised of 5.9% salary and 94.1% bonuses, including company stock and options. directly owns 0.33% of the company’s shares, worth $11.68M. The average tenure of the management team and the board of directors is 5.3 years and 5.7 years respectively.
Key information
Sam Kulkarni
Chief executive officer
US$12.3m
Total compensation
| CEO salary percentage | 5.9% |
| CEO tenure | 7.2yrs |
| CEO ownership | 0.3% |
| Management average tenure | 5.3yrs |
| Board average tenure | 5.7yrs |
Recent management updates
Recent updates
CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers
Jan 16CRISPR Therapeutics AG's (NASDAQ:CRSP) Share Price Not Quite Adding Up
Dec 31
Crispr Therapeutics: From Casgevy Success To A Catalyst-Rich 2025
Dec 29Here's Why We're Not Too Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation
Dec 03Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism
Nov 11Here's What Analysts Are Forecasting For CRISPR Therapeutics AG (NASDAQ:CRSP) After Its Third-Quarter Results
Nov 07Crispr Therapeutics: Poised For A Major Turnaround
Oct 28CRISPR Therapeutics AG (NASDAQ:CRSP) Investors Are Less Pessimistic Than Expected
Oct 02Crispr Therapeutics: Casgevy Now Active Across 35 Treatment Centres
Sep 13Here's Why We're Not At All Concerned With CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation
Sep 04Crispr's Casgevy Launch: Promising Start, Uncertain Future
Aug 14A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Aug 09Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential
Aug 07Crispr Therapeutics Remains Expensive, With Slower Casgevy Monetization And Patent Battle
Jul 13Crispr Therapeutics: Beaten Down But Not Broken
Jul 07CRISPR Therapeutics AG's (NASDAQ:CRSP) Share Price Could Signal Some Risk
Jun 18Crispr Therapeutics, Futurism-Turning-Commercial, Defies 'Valuation' (Technical Analysis)
Jun 10Crispr Therapeutics' Strategic Moves Amidst Gene Therapy Challenges (Rating Upgrade)
Jun 03Shareholders Will Probably Hold Off On Increasing CRISPR Therapeutics AG's (NASDAQ:CRSP) CEO Compensation For The Time Being
May 23Newsflash: CRISPR Therapeutics AG (NASDAQ:CRSP) Analysts Have Been Trimming Their Revenue Forecasts
May 13We're Not Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn
May 10Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg
May 09Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)
May 03Crispr Therapeutics: Now Is The Time To Buy
Apr 24Calculating The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Apr 16Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape
Mar 26There's Reason For Concern Over CRISPR Therapeutics AG's (NASDAQ:CRSP) Massive 26% Price Jump
Feb 22Crispr Therapeutics: Cautiously Optimistic
Feb 22Crispr Therapeutics: Investors Bet Against Casgevy Uptake
Feb 01Crispr Therapeutics: Commercial Validation Is The Next Step
Jan 18Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry
Jan 11CRISPR Therapeutics AG's (NASDAQ:CRSP) Popularity With Investors Is Under Threat From Overpricing
Dec 25CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Nov 02A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Oct 05CRISPR Therapeutics AG's (NASDAQ:CRSP) Business Is Yet to Catch Up With Its Share Price
Sep 14We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate
Jul 24Calculating The Fair Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Jun 28CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Apr 02CRISPR Therapeutics AG's (NASDAQ:CRSP) Intrinsic Value Is Potentially 34% Above Its Share Price
Mar 06Companies Like CRISPR Therapeutics (NASDAQ:CRSP) Are In A Position To Invest In Growth
Dec 08CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$240m |
| Jun 30 2024 | n/a | n/a | -US$266m |
| Mar 31 2024 | n/a | n/a | -US$217m |
| Dec 31 2023 | US$12m | US$725k | -US$154m |
| Sep 30 2023 | n/a | n/a | -US$354m |
| Jun 30 2023 | n/a | n/a | -US$416m |
| Mar 31 2023 | n/a | n/a | -US$524m |
| Dec 31 2022 | US$21m | US$700k | -US$650m |
| Sep 30 2022 | n/a | n/a | -US$681m |
| Jun 30 2022 | n/a | n/a | -US$633m |
| Mar 31 2022 | n/a | n/a | US$312m |
| Dec 31 2021 | US$17m | US$670k | US$378m |
| Sep 30 2021 | n/a | n/a | US$412m |
| Jun 30 2021 | n/a | n/a | US$447m |
| Mar 31 2021 | n/a | n/a | -US$392m |
| Dec 31 2020 | US$9m | US$625k | -US$349m |
| Sep 30 2020 | n/a | n/a | -US$211m |
| Jun 30 2020 | n/a | n/a | US$20m |
| Mar 31 2020 | n/a | n/a | US$46m |
| Dec 31 2019 | US$16m | US$550k | US$67m |
| Sep 30 2019 | n/a | n/a | -US$11m |
| Jun 30 2019 | n/a | n/a | -US$200m |
| Mar 31 2019 | n/a | n/a | -US$185m |
| Dec 31 2018 | US$10m | US$518k | -US$165m |
Compensation vs Market: Sam's total compensation ($USD12.32M) is above average for companies of similar size in the US market ($USD6.64M).
Compensation vs Earnings: Sam's compensation has been consistent with company performance over the past year.
CEO
Sam Kulkarni (46 yo)
7.2yrs
Tenure
US$12,322,196
Compensation
Dr. Samarth Kulkarni, Ph D, also known as Sam, has been an Independent Director of Repare Therapeutics Inc. since November 2019. Dr. Kulkarni serves as Independent Director of Oruka Therapeutics, Inc since...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 7.2yrs | US$12.32m | 0.33% $ 11.7m | |
| Chief Financial Officer | 1.9yrs | US$5.91m | 0.012% $ 416.0k | |
| General Counsel & Secretary | 7.8yrs | US$3.51m | 0.073% $ 2.6m | |
| Founder | no data | no data | no data | |
| Co-Founder & Scientific Advisory Board Member | no data | no data | no data | |
| Scientific Founder & Advisory Board Member | no data | no data | no data | |
| Scientific Founder | no data | no data | no data | |
| Scientific Founder & Advisory Board Member | no data | no data | no data | |
| Scientific Founder & Advisory Board Member | no data | no data | no data | |
| Chief Operating Officer | less than a year | no data | 0.016% $ 575.4k | |
| Head of Technical Operations | 5.3yrs | no data | no data | |
| Vice President of Corporate Communications & Investor Relations | no data | no data | no data |
5.3yrs
Average Tenure
49yo
Average Age
Experienced Management: CRSP's management team is seasoned and experienced (5.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 6.7yrs | US$12.32m | 0.33% $ 11.7m | |
| Co-Founder & Scientific Advisory Board Member | no data | no data | no data | |
| Scientific Founder & Advisory Board Member | no data | no data | no data | |
| Scientific Founder & Advisory Board Member | no data | no data | no data | |
| Scientific Founder & Advisory Board Member | no data | no data | no data | |
| Lead Independent Director | 4.7yrs | US$552.56k | 0.0023% $ 83.1k | |
| Independent Director | 9.8yrs | US$545.06k | 0.00032% $ 11.4k | |
| Independent Director | 5.7yrs | US$532.56k | 0% $ 0 | |
| Independent Director | 9.8yrs | US$542.56k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.7yrs | US$555.06k | 0% $ 0 | |
| Independent Director | 3.7yrs | US$536.24k | 0% $ 0 |
5.7yrs
Average Tenure
58yo
Average Age
Experienced Board: CRSP's board of directors are considered experienced (5.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/02 02:05 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CRISPR Therapeutics AG is covered by 46 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Huidong Wang | Barclays |
| Evan Seigerman | BMO Capital Markets Equity Research |